


A β -IN-6

Cat. No.:	HY-149246
Molecular Formula:	C ₂₈ H ₃₁ N ₃ O ₄
Molecular Weight:	473.56
Target:	Amyloid- β ; Keap1-Nrf2
Pathway:	Neuronal Signaling; NF- κ B
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	A β -IN-6 reduces pro-inflammatory cytokine release from microglia cells. A β -IN-6 significantly induces Nrf2 nuclear translocation and hampers A β oligomers formation. A β -IN-6 exerts a consistent neuroprotective effect by modulating the redox-sensitive signalling pathways in vivo oxidative stress model. A β -IN-6 is an orally active and has anti-inflammatory, Antioxidant and Anti-oligomeric activity. A β -IN-6 has the potential for Alzheimer's disease (AD) research ^[1] .																
In Vitro	<p>Aβ-IN-6 (compound 4; 1-20 μM; 24 h) markedly reduces microglia viability starting from the concentration of 5 μM^[1]. Aβ-IN-6 (1.25-40 μM; 24 h) causes significant cytotoxicity at concentrations higher than 2.5 μM in SH-SY5Y neuroblastoma cells^[1].</p> <p>Aβ-IN-6 (2.5 μM; 3 h) significantly induces Nrf2 nuclear translocation^[1].</p> <p>Aβ-IN-6 (2.5 μM) markedly suppresses the LPS-induced increase of mRNA levels of the two cytokines and NLRP3^[1].</p> <p>Aβ-IN-6 (1, 2.5 μM; pretreated for 1 h then stimulated with LPS for 24 h) significantly decreases LPS treatment induced the release of TNF-α and IL-1β^[1].</p> <p>Aβ-IN-6 (2.5 μM; for 24 h) before tert-butyl hydroperoxide (t-BuOOH; 50 μM for 30 min) reduces ROS formation with inhibition of around 18%^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Microglia</td> </tr> <tr> <td>Concentration:</td> <td>1-20 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h</td> </tr> <tr> <td>Result:</td> <td>Markedly reduced microglia viability starting from the concentration of 5 μM.</td> </tr> </table> <p>Cell Cytotoxicity Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>SH-SY5Y neuroblastoma cells</td> </tr> <tr> <td>Concentration:</td> <td>1.25, 2.5, 5, 10, 20, 40 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h</td> </tr> <tr> <td>Result:</td> <td>Recorded significant cytotoxicity at concentrations higher than 2.5 μM.</td> </tr> </table>	Cell Line:	Microglia	Concentration:	1-20 μ M	Incubation Time:	24 h	Result:	Markedly reduced microglia viability starting from the concentration of 5 μ M.	Cell Line:	SH-SY5Y neuroblastoma cells	Concentration:	1.25, 2.5, 5, 10, 20, 40 μ M	Incubation Time:	24 h	Result:	Recorded significant cytotoxicity at concentrations higher than 2.5 μ M.
Cell Line:	Microglia																
Concentration:	1-20 μ M																
Incubation Time:	24 h																
Result:	Markedly reduced microglia viability starting from the concentration of 5 μ M.																
Cell Line:	SH-SY5Y neuroblastoma cells																
Concentration:	1.25, 2.5, 5, 10, 20, 40 μ M																
Incubation Time:	24 h																
Result:	Recorded significant cytotoxicity at concentrations higher than 2.5 μ M.																

	<p>Western Blot Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>SH-SY5Y cells</td> </tr> <tr> <td>Concentration:</td> <td>2.5 μM 3 hSignificantly induced Nrf2 nuclear translocation.SH-SY5Y cells2.5 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>3 h</td> </tr> <tr> <td>Result:</td> <td>Significantly induced Nrf2 nuclear translocation.</td> </tr> </table> <p>RT-PCR^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Microglia</td> </tr> <tr> <td>Concentration:</td> <td>2.5 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>Pretreated for 1 h and then stimulated with 100 ng/mL LPS for 6 h</td> </tr> <tr> <td>Result:</td> <td>Markedly suppressed the LPS-induced increase of mRNA levels of the two cytokines and NLRP3, confirming the anti-inflammatory properties.</td> </tr> </table>	Cell Line:	SH-SY5Y cells	Concentration:	2.5 μ M 3 hSignificantly induced Nrf2 nuclear translocation.SH-SY5Y cells2.5 μ M	Incubation Time:	3 h	Result:	Significantly induced Nrf2 nuclear translocation.	Cell Line:	Microglia	Concentration:	2.5 μ M	Incubation Time:	Pretreated for 1 h and then stimulated with 100 ng/mL LPS for 6 h	Result:	Markedly suppressed the LPS-induced increase of mRNA levels of the two cytokines and NLRP3, confirming the anti-inflammatory properties.
Cell Line:	SH-SY5Y cells																
Concentration:	2.5 μ M 3 hSignificantly induced Nrf2 nuclear translocation.SH-SY5Y cells2.5 μ M																
Incubation Time:	3 h																
Result:	Significantly induced Nrf2 nuclear translocation.																
Cell Line:	Microglia																
Concentration:	2.5 μ M																
Incubation Time:	Pretreated for 1 h and then stimulated with 100 ng/mL LPS for 6 h																
Result:	Markedly suppressed the LPS-induced increase of mRNA levels of the two cytokines and NLRP3, confirming the anti-inflammatory properties.																
In Vivo	<p>Aβ-IN-6 (compound 4; 10 μM; added to standard food) efficiently restored the increased ROS level in larval muscles and brains under neurodegenerative conditions (D-spastin loss of function model) to that observed for the control in Spastin Drosophila model^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Spastin Drosophila model^[1]</td> </tr> <tr> <td>Dosage:</td> <td>10 μM</td> </tr> <tr> <td>Administration:</td> <td>Added to standard food (dissolved in DMSO)</td> </tr> <tr> <td>Result:</td> <td>Efficiently restored the increased ROS level in larval muscles and brains under neurodegenerative conditions (D-spastin loss of function model) to that observed for the control. Significantly ameliorated the phenotype associated with spastin reduction.</td> </tr> </table>	Animal Model:	Spastin Drosophila model ^[1]	Dosage:	10 μ M	Administration:	Added to standard food (dissolved in DMSO)	Result:	Efficiently restored the increased ROS level in larval muscles and brains under neurodegenerative conditions (D-spastin loss of function model) to that observed for the control. Significantly ameliorated the phenotype associated with spastin reduction.								
Animal Model:	Spastin Drosophila model ^[1]																
Dosage:	10 μ M																
Administration:	Added to standard food (dissolved in DMSO)																
Result:	Efficiently restored the increased ROS level in larval muscles and brains under neurodegenerative conditions (D-spastin loss of function model) to that observed for the control. Significantly ameliorated the phenotype associated with spastin reduction.																

REFERENCES

[1]. Ersilia De Lorenzi, et al. Targeting the multifaceted neurotoxicity of Alzheimer's disease by tailored functionalisation of the curcumin scaffold. Eur J Med Chem. 2023 Apr 5;252:115297.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA